» Articles » PMID: 34299151

PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jul 24
PMID 34299151
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Coagulopathies common to patients with diabetes and chronic kidney disease (CKD) are not fully understood. Fibrin deposits in the kidney suggest the local presence of clotting factors including tissue factor (TF). In this study, we investigated the effect of glucose availability on the synthesis of TF by cultured human kidney tubular epithelial cells (HTECs) in response to activation of protease-activated receptor 2 (PAR2). PAR2 activation by peptide 2f-LIGRLO-NH (2F, 2 µM) enhanced the synthesis and secretion of active TF (~45 kDa) which was blocked by a PAR2 antagonist (I-191). Treatment with 2F also significantly increased the consumption of glucose from the cell medium and lactate secretion. Culturing HTECs in 25 mM glucose enhanced TF synthesis and secretion over 5 mM glucose, while addition of 5 mM 2-deoxyglucose (2DOG) significantly decreased TF synthesis and reduced its molecular weight (~40 kDa). Blocking glycosylation with tunicamycin also reduced 2F-induced TF synthesis while reducing its molecular weight (~36 kDa). In conclusion, PAR2-induced TF synthesis in HTECs is enhanced by culture in high concentrations of glucose and suppressed by inhibiting either PAR2 activation (I-191), glycolysis (2DOG) or glycosylation (tunicamycin). These results may help explain how elevated concentrations of glucose promote clotting abnormities in diabetic kidney disease. The application of PAR2 antagonists to treat CKD should be investigated further.

Citing Articles

The Many Faces of Protease-Activated Receptor 2 in Kidney Injury.

Oe Y, Tanaka T, Takahashi N Biomedicines. 2025; 13(2).

PMID: 40002827 PMC: 11852827. DOI: 10.3390/biomedicines13020414.


Metabolite pathway alterations identified by magnetic resonance metabolomics in a proximal tubular epithelial cell line treated with TGF-β1.

Humphries T, Lee S, Urquhart A, Vesey D, Micallef A, Winterford C Physiol Rep. 2025; 13(4):e70249.

PMID: 39957082 PMC: 11830627. DOI: 10.14814/phy2.70249.


Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels.

Fernandez-Santiago R, Esteve-Codina A, Fernandez M, Valldeoriola F, Sanchez-Gomez A, Munoz E NPJ Parkinsons Dis. 2021; 7(1):109.

PMID: 34853332 PMC: 8636510. DOI: 10.1038/s41531-021-00255-x.

References
1.
Watanabe M, Oe Y, Sato E, Sekimoto A, Sato H, Ito S . Protease-activated receptor 2 exacerbates cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2019; 316(4):F654-F659. DOI: 10.1152/ajprenal.00489.2018. View

2.
Jiang Y, Yau M, Lim J, Wu K, Xu W, Suen J . A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther. 2017; 364(2):246-257. DOI: 10.1124/jpet.117.245027. View

3.
Nystedt S, Ramakrishnan V, Sundelin J . The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem. 1996; 271(25):14910-5. DOI: 10.1074/jbc.271.25.14910. View

4.
Mather A, Pollock C . Glucose handling by the kidney. Kidney Int Suppl. 2011; (120):S1-6. DOI: 10.1038/ki.2010.509. View

5.
Cimmino G, Cirillo P . Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther. 2018; 8(5):581-593. PMC: 6232348. DOI: 10.21037/cdt.2018.10.14. View